NorthWest Biotherapeutics Inc (NWBO)

[JerryCampbell]

10-Q first pass

https://www.sec.gov/Archives/edgar/data/1072379/000114420419025347/tv521011_10q.htm

Shares outstanding: 537m, up 14m, with most of the increase from conversion of debt and accrued interest.

Cash: 16.3m, down 5.9m

Some changes for new lease accounting standards. You now see a "right-of-use" asset 4.8m, also a lease liability 4.7m

Total Operating costs: 8.1m

New note 4.4m entered 3/29/2019 with 8% interest, 10% OID, and a 15% prepayment penalty

Potentially dilutive securities: 499m, down 9.4m, with a new item "Contingently issuable warrants" of 11.7m. I saw no explanation for the new item.

No quarterly expenses with Cognate.

New subsidiary in the Netherlands.

Subsequent events include issuance of 7.4m shares.